{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:30:38Z","timestamp":1793136638277,"version":"4.5.0"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.lfs.2024.123001","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T11:43:08Z","timestamp":1724326988000},"page":"123001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges"],"prefix":"10.1016","volume":"355","author":[{"given":"Jacky","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneh","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Rockcole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.123001_bb0005","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.lfs.2024.123001_bb0010","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2666-7568(24)00061-8","article-title":"Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis","volume":"5","author":"Stephan","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.lfs.2024.123001_bb0015","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.1212\/WNL.0000000000208284","article-title":"Machine learning-enhanced dementia testing: reliability and accuracy of the autonomous cognitive examination (S1.008)","volume":"102","author":"Howard","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2024.123001_bb0020","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.lfs.2024.123001_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2016.04.020","article-title":"Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models","volume":"44","author":"Zhao","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.lfs.2024.123001_bb0030","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1523\/JNEUROSCI.2016-16.2016","article-title":"Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice","volume":"36","author":"Liu","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0035","series-title":"Rab GTPase Proteins in Tauopathy (5236)","author":"McFarland","year":"2020"},{"key":"10.1016\/j.lfs.2024.123001_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101594","article-title":"APOE mediated neuroinflammation and neurodegeneration in Alzheimer\u2019s disease","volume":"59","author":"Parhizkar","year":"2022","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.lfs.2024.123001_bb0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s12276-023-01146-2","article-title":"Current understanding of the Alzheimer\u2019s disease-associated microbiome and therapeutic strategies","volume":"56","author":"Seo","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lfs.2024.123001_bb0050","series-title":"From Lab Bench to Hope: Emerging Gene Therapies in Clinical Trials for Alzheimer\u2019s Disease","author":"Ortega","year":"2024"},{"key":"10.1016\/j.lfs.2024.123001_bb0055","first-page":"362","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0060","series-title":"Aducanumab","author":"Padda","year":"2024"},{"key":"10.1016\/j.lfs.2024.123001_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer\u2019s disease: a focus on aducanumab and lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0070","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.lfs.2024.123001_bb0075","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/1570159X14666151208112754","article-title":"Current treatment options for Alzheimer\u2019s disease and Parkinson\u2019s disease dementia","volume":"14","author":"Szeto","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0080","article-title":"The link between diabetes mellitus and tau hyperphosphorylation: implications for risk of Alzheimer\u2019s disease","volume":"13","author":"Hobday","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.lfs.2024.123001_bb0085","first-page":"23","article-title":"Type 2 diabetes mellitus and Alzheimer\u2019s disease: shared molecular mechanisms and potential common therapeutic targets","author":"Hamz\u00e9","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.123001_bb0090","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/db13-1954","article-title":"Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease","volume":"63","author":"De Felice","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2024.123001_bb0095","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.2337\/dc17-0330","article-title":"The role of hyperglycemia, insulin resistance, and blood pressure in diabetes-associated differences in cognitive performance\u2014the Maastricht study","volume":"40","author":"Geijselaers","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2024.123001_bb0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123001_bb0105","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","article-title":"Brain insulin resistance in Alzheimer\u2019s disease and related disorders: mechanisms and therapeutic approaches","volume":"19","author":"Kellar","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.lfs.2024.123001_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archneurol.2008.579","article-title":"Different patterns of cerebral injury in dementia with or without diabetes","volume":"66","author":"Sonnen","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.lfs.2024.123001_bb0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11597760-000000000-00000","article-title":"Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer\u2019s disease","volume":"72","author":"de la Monte","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2024.123001_bb0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuroscience.2023.08.033","article-title":"Alzheimer\u2019s disease in diabetic patients: a lipidomic prospect","volume":"530","author":"Makki","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2024.123001_bb0125","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000510677","article-title":"Antidiabetic drugs in Alzheimer\u2019s disease and mild cognitive impairment: a systematic review","volume":"49","author":"Mu\u00f1oz-Jim\u00e9nez","year":"2020","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.lfs.2024.123001_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114578","article-title":"GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer\u2019s disease by regulating mitochondrial dysfunction via the cAMP\/PKA pathway","volume":"188","author":"Xie","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neuint.2019.04.006","article-title":"Exendin-4 attenuates brain mitochondrial toxicity through PI3K\/Akt-dependent pathway in amyloid beta (1-42)-induced cognitive deficit rats","volume":"128","author":"Garabadu","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.lfs.2024.123001_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101180","article-title":"GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer\u2019s disease","volume":"47","author":"Zheng","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.lfs.2024.123001_bb0145","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.11.114","article-title":"Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP\/PS1\/tau mouse model of Alzheimer\u2019s disease","volume":"495","author":"Cai","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2024.123001_bb0150","first-page":"21","article-title":"Liraglutide protects against brain amyloid-\u03b2","author":"Duarte","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.123001_bb0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","article-title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-\u03b2 plaque and glial pathology in a mouse model of Alzheimer\u2019s disease","volume":"15","author":"Long-Smith","year":"2013","journal-title":"Neuromolecular Med."},{"issue":"Pt A","key":"10.1016\/j.lfs.2024.123001_bb0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease","volume":"76","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuroscience.2014.02.022","article-title":"Lixisenatide rescues spatial memory and synaptic plasticity from amyloid \u03b2 protein-induced impairments in rats","volume":"277","author":"Cai","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2024.123001_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2016.04.052","article-title":"Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3\u03b2 pathway in an amyloid \u03b2 protein induced alzheimer disease mouse model","volume":"783","author":"Qi","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116566","article-title":"The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis","volume":"231","author":"Yan","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2024.123001_bb0180","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainres.2015.12.052","article-title":"The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy","volume":"1634","author":"Hansen","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1505","article-title":"The novel GLP-1\/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD","volume":"10","author":"Li","year":"2020","journal-title":"Brain Behav."},{"key":"10.1016\/j.lfs.2024.123001_bb0190","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejphar.2011.11.005","article-title":"(Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains","volume":"674","author":"Li","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2019.04.018","article-title":"Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R\/Akt\/GSK3\u03b2 signaling","volume":"153","author":"Shu","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0200","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mcn.2015.10.005","article-title":"Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level","volume":"70","author":"Yang","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111529","article-title":"Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer\u2019s disease by suppressing NLRP2 activation in astrocytes","volume":"542","author":"Zhang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123001_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101457","article-title":"Regulation of neuroinflammation with GLP-1 receptor targeting nanostructures to alleviate Alzheimer\u2019s symptoms in the disease models","volume":"44","author":"Zhao","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.lfs.2024.123001_bb0215","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3233\/JAD-190237","article-title":"Exenatide reverts the high-fat-diet-induced impairment of BDNF signaling and inflammatory response in an animal model of Alzheimer\u2019s disease","volume":"70","author":"Bomba","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.111932","article-title":"Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5\u00d7FAD mouse model of Alzheimer\u2019s disease","volume":"370","author":"An","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0225","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11064-021-03442-7","article-title":"Liraglutide alleviates cognitive deficit in db\/db mice: involvement in oxidative stress, iron overload, and ferroptosis","volume":"47","author":"An","year":"2022","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.741923","article-title":"Liraglutide reduces vascular damage, neuronal loss, and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes","volume":"13","author":"Carranza-Naval","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0235","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1007\/s11064-017-2250-8","article-title":"Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of tau and neurofilaments in APP\/PS1\/tau triple transgenic mice","volume":"42","author":"Chen","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0240","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3233\/JAD-143090","article-title":"The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer\u2019s disease","volume":"46","author":"Hansen","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0245","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3233\/JAD-143090","article-title":"The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer\u2019s disease","volume":"46","author":"Hansen","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0250","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2015.07.024","article-title":"Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP\/PS1 mice","volume":"293","author":"McClean","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.111932","article-title":"Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5\u00d7 FAD mouse model of Alzheimer\u2019s disease","volume":"370","author":"An","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0260","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.peptides.2014.08.014","article-title":"Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice","volume":"61","author":"Lennox","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.lfs.2024.123001_bb0265","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00761-9","article-title":"Metformin attenuates plaque-associated tau pathology and reduces amyloid-\u03b2 burden in APP\/PS1 mice","volume":"13","author":"Chen","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.lfs.2024.123001_bb0270","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","article-title":"Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice","volume":"69","author":"Ou","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.lfs.2024.123001_bb0275","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00221-021-06176-8","article-title":"Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice","volume":"239","author":"Oliveira","year":"2021","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0280","first-page":"2315106","article-title":"Metformin ameliorates A","volume":"2020","author":"Lu","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2024.123001_bb0285","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pbb.2012.03.002","article-title":"Metformin attenuates Alzheimer\u2019s disease-like neuropathology in obese, leptin-resistant mice","volume":"101","author":"Li","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.lfs.2024.123001_bb0290","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer\u2019s-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0295","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3233\/JAD-2012-111661","article-title":"Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer\u2019s disease","volume":"30","author":"Searcy","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0300","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/npp.2010.32","article-title":"Rosiglitazone rescues memory impairment in Alzheimer\u2019s transgenic mice: mechanisms involving a reduced amyloid and tau pathology","volume":"35","author":"Escribano","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114549","article-title":"Rosiglitazone attenuates amyloid beta and glial fibrillary acidic protein in the hippocampus and neuroinflammation associated learning and memory impairments in rats","volume":"452","author":"Beheshti","year":"2023","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0310","first-page":"92","article-title":"Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer\u2019s disease","volume":"3","author":"Fernandez-Martos","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.lfs.2024.123001_bb0315","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1038\/s41598-019-40736-x","article-title":"Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus","volume":"9","author":"Seok","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.123001_bb0320","doi-asserted-by":"crossref","first-page":"10117","DOI":"10.1523\/JNEUROSCI.5268-11.2012","article-title":"Mechanisms underlying the rapid peroxisome proliferator-activated receptor-\u03b3-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer\u2019s disease","volume":"32","author":"Mandrekar-Colucci","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0325","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fnagi.2019.00178","article-title":"Pioglitazone reduces \u03b2 amyloid levels","volume":"11","author":"Quan","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0330","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","article-title":"Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice","volume":"128","author":"Heneka","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.lfs.2024.123001_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016991","article-title":"The \u03b53 and \u03b54 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice","volume":"6","author":"To","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2024.123001_bb0340","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1474-4422(21)00043-0","article-title":"Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer\u2019s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Burns","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.lfs.2024.123001_bb0345","article-title":"Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity","volume":"10","author":"Chen","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2024.123001_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.854031","article-title":"Chronic PPAR\u03b3 stimulation shifts amyloidosis to higher fibrillarity but improves cognition","volume":"14","author":"Blume","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0355","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer\u2019s disease","volume":"54","author":"Kosaraju","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.lfs.2024.123001_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108662","article-title":"Linagliptin, a DPP-4 inhibitor, ameliorates A\u03b2 (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer\u2019s disease","volume":"195","author":"Siddiqui","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107668","article-title":"DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling","volume":"157","author":"Chen","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115755","article-title":"SGLT2 and DPP4 inhibitors improve Alzheimer\u2019s disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model","volume":"168","author":"Sim","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2024.123001_bb0375","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neuropharm.2013.04.008","article-title":"Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer\u2019s disease","volume":"72","author":"Kosaraju","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0380","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.exger.2009.12.004","article-title":"Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer\u2019s prone mice","volume":"45","author":"D\u2019Amico","year":"2010","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.lfs.2024.123001_bb0385","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1007\/s11064-023-03924-w","article-title":"Neuroprotective role of DPP-4 inhibitor linagliptin against neurodegeneration, neuronal insulin resistance and neuroinflammation induced by intracerebroventricular streptozotocin in rat model of Alzheimer\u2019s disease","volume":"48","author":"Siddiqui","year":"2023","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0390","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jphp.12148","article-title":"Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer\u2019s disease","volume":"65","author":"Kosaraju","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0395","first-page":"20","article-title":"The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates high-fat induced cognitive decline in tauopathy model mice","author":"Nakaoku","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.123001_bb0400","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/acel.12498","article-title":"Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe\/PS1dE9 mice","volume":"15","author":"Mao","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.lfs.2024.123001_bb0405","first-page":"41","article-title":"Intranasal administration of insulin lowers amyloid-beta levels in rat model of diabetes","volume":"50","author":"Subramanian","year":"2012","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.lfs.2024.123001_bb0410","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.expneurol.2014.06.004","article-title":"Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces A\u03b2 level and microglia activation in the brains of 3xTg-AD mice","volume":"261","author":"Chen","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.lfs.2024.123001_bb0415","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11571-020-09571-z","article-title":"Intranasal insulin administration may be highly effective in improving cognitive function in mice with cognitive dysfunction by reversing brain insulin resistance","volume":"14","author":"Lv","year":"2020","journal-title":"Cogn. Neurodyn."},{"key":"10.1016\/j.lfs.2024.123001_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114814","article-title":"Intranasal insulin intake and exercise improve memory function in amyloid-\u03b2 induced Alzheimer\u2019s-like disease in rats: involvement of hippocampal BDNF-TrkB receptor","volume":"460","author":"Farokhi Larijani","year":"2024","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0425","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.lfs.2024.123001_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2023.114134","article-title":"The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer\u2019s disease: inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation","volume":"263","author":"Pang","year":"2023","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.lfs.2024.123001_bb0435","article-title":"Acarbose ameliorates Western diet-induced metabolic and cognitive impairments in the 3xTg mouse model of Alzheimer\u2019s disease","author":"Sonsalla","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.lfs.2024.123001_bb0440","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s10787-023-01313-x","article-title":"Voglibose attenuates cognitive impairment, A\u03b2 aggregation, oxidative stress, and neuroinflammation in streptozotocin-induced Alzheimer\u2019s disease rat model","volume":"31","author":"Rajkumar","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0445","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-160543","article-title":"Subclinical doses of ATP-sensitive potassium channel modulators prevent alterations in memory and synaptic plasticity induced by amyloid-\u03b2","volume":"57","author":"Salgado-Puga","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.112359","article-title":"Glibenclamide mitigates cognitive impairment and hippocampal neuroinflammation in rats with type 2 diabetes and sporadic Alzheimer-like disease","volume":"379","author":"Esmaeili","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0455","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejphar.2010.05.030","article-title":"Study of the effect of inhibiting galanin in Alzheimer\u2019s disease induced in rats","volume":"641","author":"Baraka","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0460","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2017.11.048","article-title":"GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer\u2019s disease models through the Akt\/GSK-3\u03b2\/\u03b2-catenin signaling","volume":"131","author":"Wang","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0465","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier","volume":"18","author":"Kastin","year":"2002","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0470","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0475","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2024.123001_bb0480","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.expneurol.2006.09.028","article-title":"Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy","volume":"203","author":"Perry","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.lfs.2024.123001_bb0485","doi-asserted-by":"crossref","first-page":"T31","DOI":"10.1530\/JOE-13-0221","article-title":"Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases","volume":"221","author":"H\u00f6lscher","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123001_bb0490","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/JIM.0000000000000129","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes","volume":"63","author":"Xu","year":"2015","journal-title":"J. Invest. Med."},{"key":"10.1016\/j.lfs.2024.123001_bb0495","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer\u2019s disease","volume":"19","author":"Li","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0500","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuroscience.2013.10.038","article-title":"Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation","volume":"256","author":"Chen","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.lfs.2024.123001_bb0505","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease-associated A\u03b2 oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2024.123001_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107813","article-title":"Neuroprotective and restorative properties of the GLP-1\/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer\u2019s disease","volume":"162","author":"Salles","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058784","article-title":"Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model","volume":"8","author":"Parthsarathy","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2024.123001_bb0520","first-page":"22","article-title":"Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer\u2019s disease","author":"Paladugu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.123001_bb0525","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0530","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","article-title":"Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease","volume":"86","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0535","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520953041","article-title":"The dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"35","author":"Maskery","year":"2020","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"10.1016\/j.lfs.2024.123001_bb0540","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3390\/ijms21051725","article-title":"Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity","volume":"21","author":"Jantrapirom","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.123001_bb0545","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.neuropharm.2018.11.002","article-title":"Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of \u03b2-amyloid pathology","volume":"144","author":"Holubov\u00e1","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0550","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0555","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2017.10.012","article-title":"Neuroprotective effects of a triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer\u2019s disease","volume":"1678","author":"Tai","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0560","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbr.2017.03.032","article-title":"A novel dual GLP-1\/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model","volume":"327","author":"Shi","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158205","article-title":"Long-term treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has no effect on \u03b2-amyloid plaque load in two transgenic APP\/PS1 mouse models of Alzheimer\u2019s disease","volume":"11","author":"Hansen","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2024.123001_bb0570","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0575","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0580","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A pilot study of exenatide actions in Alzheimer\u2019s disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0585","doi-asserted-by":"crossref","DOI":"10.1002\/alz.057848","article-title":"Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease","volume":"17","author":"Edison","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.lfs.2024.123001_bb0590","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.lfs.2024.123001_bb0595","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","article-title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease","volume":"356","author":"Watson","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0600","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jgs.18306","article-title":"Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies","volume":"71","author":"Tang","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.lfs.2024.123001_bb0605","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/dom.15331","article-title":"Diabetes, antidiabetic medications and risk of dementia: a systematic umbrella review and meta-analysis","volume":"26","author":"Kuate Defo","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2024.123001_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111825","article-title":"A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk\u2014study rationale and design","author":"Davidy","year":"2023","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.lfs.2024.123001_bb0615","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3673","article-title":"Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis","volume":"39","author":"Tian","year":"2023","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.lfs.2024.123001_bb0620","first-page":"8","article-title":"Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus sulfonylureas: a real-world population-based cohort study","author":"Kim","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2024.123001_bb0625","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/gerona\/glu032","article-title":"Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment","volume":"69","author":"Rizzo","year":"2014","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"10.1016\/j.lfs.2024.123001_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2019.06.001","article-title":"Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment","volume":"84","author":"Borz\u00ec","year":"2019","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.lfs.2024.123001_bb0635","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","article-title":"The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer\u2019s disease","volume":"123","author":"Isik","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2024.123001_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113726","article-title":"Biguanides drugs: past success stories and promising future for drug discovery","volume":"224","author":"Grytsai","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2024.123001_bb0645","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/0885066618793385","article-title":"Review of biguanide (metformin) toxicity","volume":"34","author":"Wang","year":"2019","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.lfs.2024.123001_bb0650","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1463-1326.2004.00407.x","article-title":"The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects","volume":"7","author":"James","year":"2005","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2024.123001_bb0655","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1463-1326.2004.00385.x","article-title":"Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes","volume":"7","author":"Rodr\u00edguez-Moctezuma","year":"2005","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2024.123001_bb0660","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/hrt.2003.027722","article-title":"Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study","volume":"91","author":"Stakos","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.lfs.2024.123001_bb0665","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2796.2005.01531.x","article-title":"Metformin improves endothelial function in patients with metabolic syndrome","volume":"258","author":"Vitale","year":"2005","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.lfs.2024.123001_bb0670","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5604\/01.3001.0010.3801","article-title":"Metformin \u2014 its potential anti-cancer and anti-aging effects","volume":"71","author":"Podhorecka","year":"2017","journal-title":"Postepy Hig. Med. Dosw. (Online)"},{"key":"10.1016\/j.lfs.2024.123001_bb0675","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev.pharmtox.47.120505.105304","article-title":"AMP-activated protein kinase as a drug target","volume":"47","author":"Hardie","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2024.123001_bb0680","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1471-4159.2011.07331.x","article-title":"AMP-activated protein kinase: a potential player in Alzheimer\u2019s disease","volume":"118","author":"Salminen","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2024.123001_bb0685","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","article-title":"Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study","volume":"31","author":"Koenig","year":"2017","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.lfs.2024.123001_bb0690","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-150493","article-title":"Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial","volume":"51","author":"Luchsinger","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0695","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3233\/JAD-2011-101524","article-title":"Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin","volume":"24","author":"Hsu","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0700","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0000000000004586","article-title":"Metformin vs sulfonylurea use and risk of dementia in US veterans aged \u226565\u00a0years with diabetes","volume":"89","author":"Orkaby","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2024.123001_bb0705","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pnpbp.2017.06.002","article-title":"Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus","volume":"79","author":"Kuan","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.lfs.2024.123001_bb0710","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2337\/dc13-0229","article-title":"Increased risk of cognitive impairment in patients with diabetes is associated with metformin","volume":"36","author":"Moore","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2024.123001_bb0715","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer\u2019s disease: a population-based case-control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.lfs.2024.123001_bb0720","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/02698811211057304","article-title":"The effect of metformin on cognitive function: a systematic review and meta-analysis","volume":"36","author":"Tabatabaei Malazy","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0725","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3233\/JAD-220180","article-title":"Association between metformin and Alzheimer\u2019s disease: a systematic review and meta-analysis of clinical observational studies","volume":"88","author":"Luo","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0730","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/brain\/awad366","article-title":"Metformin in elderly type 2 diabetes mellitus: dose-dependent dementia risk reduction","volume":"147","author":"Sun","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.lfs.2024.123001_bb0735","doi-asserted-by":"crossref","first-page":"17321","DOI":"10.1523\/JNEUROSCI.1569-12.2012","article-title":"PPAR\u03b3\/RXR\u03b1-induced and CD36-mediated microglial amyloid-\u03b2 phagocytosis results in cognitive improvement in amyloid precursor protein\/presenilin 1 mice","volume":"32","author":"Yamanaka","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0740","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210106","article-title":"Long-term pioglitazone treatment has no significant impact on microglial activation and tau pathology in P301S mice","volume":"24","author":"Kunze","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.123001_bb0745","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ana.24439","article-title":"Effect of pioglitazone medication on the incidence of dementia","volume":"78","author":"Heneka","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.lfs.2024.123001_bb0750","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","article-title":"Efficacy of PPAR-\u03b3 agonist pioglitazone in mild Alzheimer disease","volume":"32","author":"Sato","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.lfs.2024.123001_bb0755","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.4103\/0028-3886.391397","article-title":"Drug repositioning of pioglitazone in management and improving the cognitive function among the patients with mild to moderate Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"71","author":"Basutkar","year":"2023","journal-title":"Neurol. India"},{"key":"10.1016\/j.lfs.2024.123001_bb0760","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-024-01558-1","article-title":"Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer\u2019s disease therapy","author":"Wong","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0765","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2024.123001_bb0770","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.2337\/db14-0375","article-title":"Insulin reverses the high-fat diet-induced increase in brain A\u03b2 and improves memory in an animal model of Alzheimer disease","volume":"63","author":"Vandal","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2024.123001_bb0775","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1096\/fj.03-0978fje","article-title":"Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer\u2019s disease","volume":"18","author":"Ho","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2024.123001_bb0780","doi-asserted-by":"crossref","first-page":"13635","DOI":"10.1523\/JNEUROSCI.3949-07.2007","article-title":"Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms","volume":"27","author":"Planel","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2024.123001_bb0785","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-150072","article-title":"Insulin resistance is associated with higher cerebrospinal fluid tau levels in asymptomatic APOEvarepsilon4 carriers","volume":"46","author":"Starks","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0790","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","article-title":"Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype","volume":"27","author":"Reger","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.lfs.2024.123001_bb0795","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2024.123001_bb0800","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0805","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3233\/JAD-161256","article-title":"Effects of regular and long-acting insulin on cognition and Alzheimer\u2019s disease biomarkers: a pilot clinical trial","volume":"57","author":"Craft","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0810","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.lfs.2024.123001_bb0815","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3233\/JAD-122308","article-title":"Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer\u2019s disease","volume":"35","author":"Claxton","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0820","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3233\/JAD-141791","article-title":"Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer\u2019s disease dementia","volume":"44","author":"Claxton","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0825","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3233\/JAD-159002","article-title":"Long acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer\u2019s disease dementia","volume":"45","author":"Claxton","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0830","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial","volume":"77","author":"Craft","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.lfs.2024.123001_bb0835","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40266-021-00845-7","article-title":"A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer\u2019s disease","volume":"38","author":"Rosenbloom","year":"2021","journal-title":"Drugs Aging"},{"key":"10.1016\/j.lfs.2024.123001_bb0840","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41598-022-05165-3","article-title":"Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer\u2019s disease: a randomized trial","volume":"12","author":"Kellar","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.123001_bb0845","first-page":"240","article-title":"Intranasal insulin reduces white matter hyperintensity progression in association with improvements in cognition and CSF biomarker profiles in mild cognitive impairment and Alzheimer\u2019s disease","volume":"8","author":"Kellar","year":"2021","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0850","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-180578","article-title":"Extracellular vesicle biomarkers track cognitive changes following intranasal insulin in Alzheimer\u2019s disease","volume":"69","author":"Mustapic","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0855","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s10787-022-00973-5","article-title":"Dapagliflozin as an autophagic enhancer via LKB1\/AMPK\/SIRT1 pathway in ovariectomized\/d-galactose Alzheimer\u2019s rat model","volume":"30","author":"Ibrahim","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.lfs.2024.123001_bb0860","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0865","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123001_bb0870","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3233\/JAD-215678","article-title":"Association between use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and cognitive function in a longitudinal study of patients with type 2 diabetes","volume":"87","author":"Low","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0875","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2024.123001_bb0880","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1080\/07391102.2021.1930583","article-title":"Repositioning of antidiabetic drugs for Alzheimer\u2019s disease: possibility of Wnt signaling modulation by targeting LRP6 an","volume":"40","author":"Manandhar","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.lfs.2024.123001_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2024.04.014","article-title":"Risk of dementia and Alzheimer\u2019s disease associated with antidiabetics: a Bayesian network meta-analysis","author":"Sunwoo","year":"2024","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.lfs.2024.123001_bb0890","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2174\/1570159X21999221111102343","article-title":"Linking diabetes to Alzheimer\u2019s disease: potential roles of glucose metabolism and alpha-glucosidase","volume":"21","author":"Wee","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.lfs.2024.123001_bb0895","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/14756366.2017.1368503","article-title":"\u03b1-Glucosidase inhibition by flavonoids: an in vitro and in silico structure-activity relationship study","volume":"32","author":"Proen\u00e7a","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.lfs.2024.123001_bb0900","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ejmech.2018.07.073","article-title":"A comprehensive review on xanthone derivatives as \u03b1-glucosidase inhibitors","volume":"157","author":"Santos","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2024.123001_bb0905","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-2007-979837","article-title":"Mechanisms of the glycaemic effects of sulfonylureas","volume":"28","author":"Ashcroft","year":"1996","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.lfs.2024.123001_bb0910","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s11011-023-01225-3","article-title":"Crosstalk between Alzheimer\u2019s disease and diabetes: a focus on anti-diabetic drugs","volume":"38","author":"Goodarzi","year":"2023","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.lfs.2024.123001_bb0915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212293","article-title":"Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer\u2019s disease: pooled analysis from 5 cohorts","volume":"14","author":"Weinstein","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2024.123001_bb0920","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/alz.12161","article-title":"Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer\u2019s disease, and the role APOE carrier status","volume":"16","author":"Wu","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.lfs.2024.123001_bb0925","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1111\/jgs.18397","article-title":"Association of sulfonylureas with the risk of dementia: a population-based cohort study","volume":"71","author":"Wu","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.lfs.2024.123001_bb0930","first-page":"10","article-title":"Comparative effect of metformin versus sulfonylureas with dementia and Parkinson\u2019s disease risk in US patients over 50 with type 2 diabetes mellitus","author":"Newby","year":"2022","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.lfs.2024.123001_bb0935","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40035-024-00417-w","article-title":"Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer\u2019s disease","volume":"13","author":"Penny","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.lfs.2024.123001_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102193","article-title":"Navigating the dementia landscape: biomarkers and emerging therapies","volume":"94","author":"Maheshwari","year":"2024","journal-title":"Ageing Res. Rev."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524005915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524005915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:16:46Z","timestamp":1725236206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524005915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":188,"alternative-id":["S0024320524005915"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123001","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123001"}}